Therefore, we designed xenograft-tumor-bearing mouse therapeutic models to evaluate GCSC susceptibility to pharmaceutical intervention after LGSN-knockdown and the lessening of cancer severity in vivo. The gene discussed is LGSN; the disease is neoplasm.